A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas

LESSONS LEARNED. The combination of the antiangiogenic agent ziv‐aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested. Studies such as these emphasize the importance of con...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Meehan, Robert, Kummar, Shivaani, Do, Khanh, O'Sullivan Coyne, Geraldine, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Doroshow, James H., Chen, Alice P.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2018
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291327/
https://ncbi.nlm.nih.gov/pubmed/29853657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0203
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky